K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · ELI LILLY AND COMPANY
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | LLY | ELI LILLY AND COMPANY | TODD STRATEGY GROUP | $80K | Alzheimer's Disease. Anti Obesity Medication. Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program. |
| 2026-04-20 | LLY | ELI LILLY AND COMPANY | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, non-interference, drug shortages, prescription drug access and affordability, transparency, insulin policy, drug pricing in federal programs Medicare & Medicaid payment and coverage issues, Medicare Part D, Medicare Part B, drug pricing in federal programs federal budget issues |
| 2026-04-20 | LLY | ELI LILLY AND COMPANY | MONUMENT ADVOCACY | $40K | Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. |
| 2026-04-18 | LLY | ELI LILLY AND COMPANY | TIBER CREEK HEALTH STRATEGIES, INC. | $80K | |
| 2026-04-17 | LLY | ELI LILLY AND COMPANY | MARSHALL & POPP, LLC | $60K | Issues related to treatments for Alzheimers therapeutics. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program. |
| 2026-04-17 | LLY | ELI LILLY AND COMPANY | FEROX STRATEGIES | $60K | Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products. |
| 2026-04-16 | LLY | ELI LILLY AND COMPANY | ELI LILLY AND COMPANY | $3.8M | Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care Intellectual property; 340B Program; Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality |
| 2026-04-16 | LLY | ELI LILLY AND COMPANY | GRV STRATEGIES LLC | $60K | Issues related to healthcare Issues related to trade |
| 2026-04-15 | LLY | ELI LILLY AND COMPANY | CHECKMATE GOVERNMENT RELATIONS | $120K | There is no specific bill filed. Engagement relates to issues on healthcare and trade. There is no specific bill filed. Engagement relates to issues on healthcare and trade. |
| 2026-04-15 | LLY | ELI LILLY AND COMPANY | VENN STRATEGIES | $50K | General Healthcare issues, including drug accessibility, importation and innovation policies. |
| 2026-01-20 | LLY | ELI LILLY AND COMPANY | CHECKMATE GOVERNMENT RELATIONS | $120K | There is no specific bill filed. Engagement relates to issues on healthcare and trade. There is no specific bill filed. Engagement relates to issues on healthcare and trade. |
| 2026-01-20 | LLY | ELI LILLY AND COMPANY | TODD STRATEGY GROUP | $80K | Alzheimer's Disease. Anti Obesity Medication. Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program. |
| 2026-01-20 | LLY | ELI LILLY AND COMPANY | GRV STRATEGIES LLC | $60K | Issues related to trade Issues related to healthcare |
| 2026-01-20 | LLY | ELI LILLY AND COMPANY | FEROX STRATEGIES | $60K | Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products. |
| 2026-01-20 | LLY | ELI LILLY AND COMPANY | TARPLIN, DOWNS & YOUNG, LLC | $60K | Medicare & Medicaid payment and coverage issues, Medicare Part D, Medicare Part B, drug pricing in federal programs federal budget issues IRA, non-interference, drug shortages, prescription drug access and affordability, transparency, insulin policy, drug pricing in federal programs |
| 2026-01-20 | LLY | ELI LILLY AND COMPANY | VENN STRATEGIES | $50K | General Healthcare issues, including drug accessibility, importation and innovation policies. |
| 2026-01-20 | LLY | ELI LILLY AND COMPANY | MONUMENT ADVOCACY | $40K | Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. |
| 2026-01-17 | LLY | ELI LILLY AND COMPANY | TIBER CREEK HEALTH STRATEGIES, INC. | $80K | |
| 2026-01-16 | LLY | ELI LILLY AND COMPANY | MARSHALL & POPP, LLC | $60K | Issues related to treatments for Alzheimers therapeutics. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program. |
| 2026-01-15 | LLY | ELI LILLY AND COMPANY | ELI LILLY AND COMPANY | $2.2M | Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1) Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1) Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; |
| 2025-10-20 | LLY | ELI LILLY AND COMPANY | CHECKMATE GOVERNMENT RELATIONS | $120K | There is no specific bill filed. Engagement relates to issues on healthcare and trade. There is no specific bill filed. Engagement relates to issues on healthcare and trade. |
| 2025-10-20 | LLY | ELI LILLY AND COMPANY | TIBER CREEK HEALTH STRATEGIES, INC. | $80K | |
| 2025-10-20 | LLY | ELI LILLY AND COMPANY | MARSHALL & POPP, LLC | $60K | Issues related to treatments for Alzheimers therapeutics. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program. |
| 2025-10-20 | LLY | ELI LILLY AND COMPANY | FEROX STRATEGIES | $60K | Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products. |
| 2025-10-20 | LLY | ELI LILLY AND COMPANY | VENN STRATEGIES | $50K | General Healthcare issues, including drug accessibility, importation and innovation policies. |
| 2025-10-20 | LLY | ELI LILLY AND COMPANY | MONUMENT ADVOCACY | $40K | Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. |
| 2025-10-16 | LLY | ELI LILLY AND COMPANY | ELI LILLY AND COMPANY | $3.4M | Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality Pharmaceutical intellectual property iss |
| 2025-10-16 | LLY | ELI LILLY AND COMPANY | ELI LILLY AND COMPANY | $2.7M | Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1) Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1) Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescrip |
| 2025-10-16 | LLY | ELI LILLY AND COMPANY | ELI LILLY AND COMPANY | $2.3M | Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1) Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1) Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; |
| 2025-10-16 | LLY | ELI LILLY AND COMPANY | ELI LILLY AND COMPANY | $1.9M | Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care. Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug v |
| 2025-10-16 | LLY | ELI LILLY AND COMPANY | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, non-interference, drug shortages, prescription drug access and affordability, transparency, insulin policy, drug pricing in federal programs Medicare & Medicaid payment and coverage issues, Medicare Part D, Medicare Part B, drug pricing in federal programs federal budget issues |
| 2025-10-12 | LLY | ELI LILLY AND COMPANY | TODD STRATEGY GROUP | $80K | Alzheimer's Disease. Anti Obesity Medication. Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program. |
| 2025-10-09 | LLY | ELI LILLY AND COMPANY | GRV STRATEGIES LLC | $60K | Issues related to healthcare Issues related to trade |
| 2025-07-21 | LLY | ELI LILLY AND COMPANY | MARSHALL & POPP, LLC | $60K | Issues related to treatments for Alzheimers therapeutics. Issues related to prescription drug value, including H.R. 1, FY25 budget reconciliation, implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program. |
| 2025-07-21 | LLY | ELI LILLY AND COMPANY | MONUMENT ADVOCACY | $40K | Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. |
| 2025-07-20 | LLY | ELI LILLY AND COMPANY | CHECKMATE GOVERNMENT RELATIONS | $120K | There is no specific bill filed. Engagement relates to issues on healthcare and trade. There is no specific bill filed. Engagement relates to issues on healthcare and trade. |
| 2025-07-19 | LLY | ELI LILLY AND COMPANY | TODD STRATEGY GROUP | $80K | Alzheimer's Disease. Anti Obesity Medication. Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program. |
| 2025-07-18 | LLY | ELI LILLY AND COMPANY | TIBER CREEK HEALTH STRATEGIES, INC. | $80K | |
| 2025-07-18 | LLY | ELI LILLY AND COMPANY | FEROX STRATEGIES | $60K | Issues related to the pharmaceutical industry. Issues related to Treating and Reducing Obesity. |
| 2025-07-18 | LLY | ELI LILLY AND COMPANY | VENN STRATEGIES | $20K | General Healthcare issues, including drug accessibility, importation and innovation policies. |
| 2025-07-17 | LLY | ELI LILLY AND COMPANY | ELI LILLY AND COMPANY | $2.7M | Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1) Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1) Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality Pharmaceutical intellectual property issues Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and |
| 2025-07-17 | LLY | ELI LILLY AND COMPANY | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, non-interference, drug shortages, prescription drug access and affordability, transparency, insulin policy, 340B Medicare & Medicaid payment and coverage issues, Medicare Part D, Medicare Part B, 340B federal budget issues |
| 2025-07-15 | LLY | ELI LILLY AND COMPANY | GRV STRATEGIES LLC | $60K | Issues related to healthcare Issues related to trade |
| 2025-04-21 | LLY | ELI LILLY AND COMPANY | TODD STRATEGY GROUP | $80K | Alzheimer's Disease. Anti Obesity Medication. Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program. |
| 2025-04-21 | LLY | ELI LILLY AND COMPANY | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, non-interference, drug shortages, prescription drug access and affordability, transparency, insulin policy, 340B Medicare & Medicaid payment and coverage issues, Medicare Part D, Medicare Part B, 340B federal budget issues |
| 2025-04-21 | LLY | ELI LILLY AND COMPANY | VENN STRATEGIES | $50K | General Healthcare issues, including drug accessibility, importation and innovation policies. |
| 2025-04-21 | LLY | ELI LILLY AND COMPANY | MONUMENT ADVOCACY | $40K | Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; Issues related to China trade; Issues related to global health; and issues related to tariffs. Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; Issues related to China trade; Issues related to global health; and issues related to tariffs. |
| 2025-04-21 | LLY | ELI LILLY AND COMPANY | CHECKMATE GOVERNMENT RELATIONS | $40K | There is no specific bill filed. Engagement relates to issues on healthcare and trade. There is no specific bill filed. Engagement relates to issues on healthcare and trade. |
| 2025-04-21 | LLY | ELI LILLY AND COMPANY | MARSHALL & POPP, LLC | $0 | Issues related to treatments for Alzheimers therapeutics. |
| 2025-04-17 | LLY | ELI LILLY AND COMPANY | TIBER CREEK HEALTH STRATEGIES, INC. | $80K | Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169). |
| 2025-04-17 | LLY | ELI LILLY AND COMPANY | FEROX STRATEGIES | $60K | Issues related to the pharmaceutical industry. Issues related to Treating and Reducing Obesity. |
| 2025-04-16 | LLY | ELI LILLY AND COMPANY | ELI LILLY AND COMPANY | $3.4M | Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality Pharmaceutical intellectual property iss |
| 2025-04-09 | LLY | ELI LILLY AND COMPANY | GRV STRATEGIES LLC | $60K | Issues related to healthcare Issues related to trade |
| 2025-03-27 | LLY | ELI LILLY AND COMPANY | CHECKMATE GOVERNMENT RELATIONS | $0 | Issues related to healthcare and trade. Issues related to healthcare and trade. |
| 2025-03-24 | LLY | ELI LILLY AND COMPANY | MARSHALL & POPP, LLC | $0 | Issues related to treatments for Alzheimers therapeutics. Issues related to treatments for Alzheimers therapeutics. Issues related to treatments for Alzheimers therapeutics. Issues related to treatments for Alzheimers therapeutics. |
| 2025-02-07 | LLY | ELI LILLY AND COMPANY | ELI LILLY AND COMPANY | $1.9M | Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care. Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's dis |